DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Feature|Videos|May 7, 2025
From Uncertainty to Opportunity: Navigating IPAY 2028
Author(s)Avalere Health
How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care
Advertisement
Omar Hafez, SVP of Market Access at Avalere Health, discusses the upcoming changes tied to the Initial Price Applicability Year (IPAY) 2028—the first year Medicare will include medical benefit drugs in its price negotiations. There are significant implications for therapeutic areas like oncology, immunology, and neurology, and this new pricing model could affect provider reimbursement and patient access. Hafez offers strategic insights for pharmaceutical manufacturers on how to prepare, including understanding the importance of real-world evidence and global pricing strategies.
Advertisement
Related to this article
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
Advertisement
Advertisement